Suppr超能文献

新型冠状病毒肺炎与肺炎:尿激酶型纤溶酶原激活物/u 型纤溶酶原激活物受体系统的作用。

COVID-19 and pneumonia: a role for the uPA/uPAR system.

机构信息

University of Naples 'Federico II', Department of Chemical Sciences, Complesso Universitario di Monte Sant'Angelo, Via Cintia 46, 80126 Naples, Italy.

University of Naples 'Federico II', Department of Chemical Sciences, Complesso Universitario di Monte Sant'Angelo, Via Cintia 46, 80126 Naples, Italy.

出版信息

Drug Discov Today. 2020 Aug;25(8):1528-1534. doi: 10.1016/j.drudis.2020.06.013. Epub 2020 Jun 18.

Abstract

Here, we highlight recent findings on the urokinase plasminogen activator (uPA)/uPA receptor (uPAR) system that suggest its potential role as a main orchestrator of fatal progression to pulmonary, kidney, and heart failure in patients with coronavirus. Patients with prolonged background inflammation can present aberrant inflammatory reactions, well recognized as the main factors that can result in death and probably sustained by a dysregulated uPA/uPAR system. SuPAR, the soluble form of uPAR, represents a biomarker of disease progression, and its levels correlate well with comorbidities associated with the death of patients with coronavirus. New drugs that regulate the uPA/uPAR system could help treat the severe complications of highly pathogenic human coronaviruses (hCoVs), including pandemic coronavirus 2019 (COVID-19).

摘要

在这里,我们强调了尿激酶型纤溶酶原激活物(uPA)/uPA 受体(uPAR)系统的最新发现,这些发现表明其可能作为冠状病毒患者发生致命性肺、肾和心力衰竭进展的主要协调因子。具有长期背景炎症的患者可能会出现异常炎症反应,这是公认的导致死亡的主要因素,可能由失调的 uPA/uPAR 系统维持。suPAR 是 uPAR 的可溶性形式,是疾病进展的生物标志物,其水平与与冠状病毒患者死亡相关的合并症密切相关。调节 uPA/uPAR 系统的新药可能有助于治疗高致病性人类冠状病毒(hCoVs)的严重并发症,包括 2019 年冠状病毒病(COVID-19)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/166b/7299864/8cb8ed831007/gr1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验